Antonio Amendola

AcomeA SGR

Largo Donegani

milano, 20121

Italy

affiliation not provided to SSRN

SCHOLARLY PAPERS

7

DOWNLOADS

1,799

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (7)

Actions:
Email selected abstracts
1.

Advanced Valuation: Modelling DCF in Continuous Time

Number of pages: 23 Posted: 23 Feb 2023
Dennis Marco Montagna, Simone Benini, Antonio Amendola and Antonio Amendola
University of Pavia - Department of Economics and Management, AcomeA SGR and affiliation not provided to SSRNAcomeA SGR
Downloads 370 (150,238)

Abstract:

Loading...

Equity Valuation, Equity, Portfolio Strategy, Asset Allocation, Valuation

2.

Spotlight on Biotechnology: valuation challenges of early-stage companies. A case study on CRISPR Therapeutics AG and Allakos, Inc.

Number of pages: 36 Posted: 31 Dec 2020
Dennis Marco Montagna, Emanuele Fino, Giovanni Nocera, Antonio Amendola and Antonio Amendola
University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management and affiliation not provided to SSRNAcomeA SGR
Downloads 289 (193,930)

Abstract:

Loading...

Equity Valuation, Biotechnology, Volatility, Return, Stock pricing, Financial modelling, Value Investing, DCF, Real Option, Black & Scholes, CRISPR Therapeutics, Allakos, CRISPR, Cas9, Monoclonal Antibodies.

3.

Stock Returns and Cash Flows: A New Asset Pricing Approach

Number of pages: 34 Posted: 24 Nov 2020 Last Revised: 29 Dec 2021
Sonia Di Tomaso, Dennis Marco Montagna, Antonio Amendola and Antonio Amendola
University of Pavia, University of Pavia - Department of Economics and Management and affiliation not provided to SSRNAcomeA SGR
Downloads 289 (193,930)

Abstract:

Loading...

Asset pricing, Volatility, Return, Quantile Regression, Stock pricing, Cash flow, Financial modelling, value investing, CAPM, Fama – French models

4.

Spotlight on Biotechnology: From a Technological Breakthrough to Valuation Challenges. A Case Study on Crispr Therapeutics and Crispr/Cas 9 Revolution.

Number of pages: 40 Posted: 04 Dec 2020 Last Revised: 05 Dec 2020
Emanuele Fino, Dennis Marco Montagna, Giovanni Nocera, Antonio Amendola and Antonio Amendola
University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management and affiliation not provided to SSRNAcomeA SGR
Downloads 262 (214,133)

Abstract:

Loading...

Valuation, Real Options, Biotechnology, CRSPR

5.

A Journey Into the Biotechnology Industry: Valuation of Early-Stage Companies. Allakos’ Case Study and the Monoclonal Antibody Therapy

Number of pages: 24 Posted: 04 Dec 2020 Last Revised: 05 Dec 2020
Giovanni Nocera, Dennis Marco Montagna, Emanuele Fino, Antonio Amendola and Antonio Amendola
University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management, University of Pavia - Department of Economics and Management and affiliation not provided to SSRNAcomeA SGR
Downloads 230 (243,244)

Abstract:

Loading...

Valuation, Real Options, Biotechnology

6.

Valuation Measures: From Simple Ratios to Stock Market’s Predictors

Number of pages: 24 Posted: 31 Dec 2020
Benedetta Sorge, Dennis Marco Montagna, Antonio Amendola and Antonio Amendola
University of Pavia, University of Pavia - Department of Economics and Management and affiliation not provided to SSRNAcomeA SGR
Downloads 198 (279,625)
Citation 1

Abstract:

Loading...

CAPE, Stock Market Returns, Returns, Risk Premium, Market Efficiency, Volatility

7.

Analysis of Equity β Principal Components in Low Risk Framework: New Results and Prospectives

Number of pages: 37 Posted: 15 Nov 2017
Antonio Amendola, Antonio Amendola, Dennis Marco Montagna and Mario Maggi
affiliation not provided to SSRNAcomeA SGR, University of Pavia - Department of Economics and Management and University of Pavia - Department of Economics and Management
Downloads 161 (335,541)

Abstract:

Loading...

Asset Allocation, Quantitative Portfolio Management, CAPM, High Beta, Low Beta, Hedge Funds, Correlation, Linear Regression